
Release date: 2026-04-09 11:45:03 Article From: Lucius Laos Recommended: 11
Do not use this product if you are allergic to larotrectinib or any other ingredients in larotrectinib capsules (such as gelatin, titanium dioxide, etc.). Before and during treatment with larotrectinib, your doctor will arrange blood tests. This is because larotrectinib may cause elevated levels of liver enzymes (such as ALAT and ASAT) and bilirubin in the blood. By monitoring these indicators through regular blood tests, your doctor can assess whether your liver function is normal to ensure safe medication use, and may adjust the treatment regimen if necessary.
Lucius Pharmaceuticals Larotrectinib may interact with other medications, affecting each other’s therapeutic effects. Therefore, you must inform your doctor of all medications you are taking, have recently taken, or plan to take, including prescription drugs, over-the-counter drugs, and herbal products. Medications requiring special attention include: itraconazole and voriconazole for fungal infections; atazanavir and ritonavir for HIV infection; phenytoin and carbamazepine for epilepsy; as well as rifampicin (for tuberculosis), St. John’s Wort (an antidepressant herb), warfarin (an anticoagulant), and statin lipid-lowering drugs. In addition, some medications for pain relief (such as fentanyl), arrhythmia control (such as quinidine), or organ rejection prevention (such as ciclosporin) may also interact with larotrectinib.
You must not consume grapefruit or drink grapefruit juice while taking larotrectinib. Grapefruit can interfere with the metabolism of the drug in the body, which may lead to an unexpected increase in plasma concentrations of larotrectinib and raise the risk of adverse reactions. In addition, larotrectinib may cause dizziness or fatigue. If you experience these symptoms after taking the medication, be sure to avoid cycling, driving motor vehicles, or operating any tools and machinery to prevent accidents. If you have questions about which foods or activities require special attention, consult your doctor or pharmacist for specific advice.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2292025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4562024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2502025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2282025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2602025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2382025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2222025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: